ADCT Stock Summary and Trading Ideas (Adc Therapeutics SA Common Shares | NYSE:ADCT)

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.

Adc Therapeutics SA Common Shares trades on the NYSE stock market under the symbol ADCT.

As of September 27, 2023, ADCT stock price declined to $0.88 with 214,884 million shares trading.

ADCT has a beta of 0.56, meaning it tends to be less sensitive to market movements. ADCT has a correlation of 0.01 to the broad based SPY ETF.

ADCT has a market cap of $70.94 million. This is considered a Micro Cap stock.

Last quarter Adc Therapeutics SA Common Shares reported $19 million in Revenue and -$.37 earnings per share. This fell short of revenue expectation by $-15 million and exceeded earnings estimates by $.07.

In the last 3 years, ADCT stock traded as high as $38.34 and as low as $.68.

The top ETF exchange traded funds that ADCT belongs to (by Net Assets): IBB.

ADCT has underperformed the market in the last year with a price return of -81.1% while the SPY ETF gained +18.7%. ADCT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -56.0% and -7.9%, respectively, while the SPY returned -0.9% and -4.1%, respectively.

ADCT support price is $.84 and resistance is $.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADCT stock will trade within this expected range on the day.